Provider Briefing: BSS Ophthalmic Solution Supply in 2026

Balanced Salt Solution (BSS) is one of the most fundamental supplies in ophthalmic surgery — so essential that its availability is often taken for granted. But the supply landscape for BSS Ophthalmic Solution has changed significantly over the past decade, and providers who aren't actively managing their procurement strategy may find themselves facing unexpected shortfalls.

This briefing covers the current state of BSS availability, the regulatory and market factors driving supply constraints, and actionable strategies for practices and surgical centers.

Timeline: How We Got Here

The BSS supply story is ultimately a tale of regulatory consolidation:

• Pre-2008: Multiple manufacturers produced balanced salt solutions for ophthalmic use, many without formal FDA approval. The market had sufficient supply and competitive pricing.
• 2008-2009: The FDA issued enforcement actions against unapproved BSS manufacturers under its initiative to remove unapproved drugs from the market. Companies were required to cease production or obtain proper approvals.
• 2009-2015: The number of BSS suppliers contracted significantly. Alcon emerged as the dominant FDA-approved manufacturer of both BSS and BSS Plus.
• Post-2015: Baxter discontinued its balanced salt solution product, further consolidating the market.
• 2024-2026: Intermittent supply tightness continues, driven by single-manufacturer dependency, rising surgical volumes, and periodic manufacturing disruptions.

Prescribing and Procurement Implications

For ophthalmologists and ASC administrators, the BSS supply situation has several practical implications:

Surgical Scheduling

BSS availability should be verified as part of pre-surgical planning, particularly during periods of known supply tightness. Practices performing high-volume cataract surgery (the most common use case for BSS) are most vulnerable to stockouts.

Product Selection

Standard BSS (Alcon) is approved for procedures with an expected duration of less than 60 minutes. For longer procedures — including complex cataracts, vitrectomy, and penetrating keratoplasty — BSS Plus is the preferred irrigating solution, offering enhanced corneal endothelial protection through its bicarbonate, dextrose, and glutathione enrichment.

Formulary Considerations

Practices should consider maintaining both BSS and BSS Plus on their formulary, along with at least one alternative product (such as Navstel or Endosol Extra). This multi-product approach provides redundancy during supply disruptions.

Current Availability Picture

As of Q1 2026, BSS Ophthalmic Solution is available but supply remains concentrated. Key data points:

• Primary manufacturer: Alcon Laboratories (Fort Worth, TX)
• Available formulations: 15 mL and 30 mL DROP-TAINER bottles (BSS); 250 mL and 500 mL glass containers (BSS Plus)
• Formal FDA shortage status: Not currently listed
• Real-world availability: Variable by region and distributor. High-volume surgical centers report intermittent difficulty sourcing adequate quantities through primary distributors.

For real-time availability data, providers can use Medfinder for Providers to identify current stock levels across multiple supply channels.

Cost and Access Considerations

Current pricing for BSS products:

• BSS Sterile Irrigating Solution (15 mL): $21-$42 per vial (wholesale)
• BSS Plus (500 mL): ~$107 per container

These costs are typically absorbed into surgical facility charges. However, practices should monitor pricing trends, as supply constraints can drive premium pricing through secondary distributors.

Insurance and reimbursement considerations: BSS is billed as part of the surgical facility fee rather than as a separate medication charge. Current CPT and HCPCS coding practices bundle irrigating solutions into the overall surgical supply reimbursement. Practices should ensure their cost-to-reimbursement margins account for potential BSS price increases.

Tools and Resources for Providers

Several resources can help practices navigate BSS supply management:

• Medfinder for Providers: Real-time availability tracking across pharmacies and surgical suppliers
• ASHP Drug Shortage Resource Center: Monitors formal shortage designations for all medications, including ophthalmic products
• FDA Drug Shortage Database: Official shortage listings and resolution timelines
• Alcon Professional Services: Direct manufacturer contact for supply chain questions and bulk ordering

For guidance on helping patients navigate the supply situation, see our companion guide: How to Help Your Patients Find BSS Ophthalmic Solution in Stock.

Alternative Products at a Glance

When standard BSS is unavailable, the following FDA-approved alternatives may be appropriate:

• BSS Plus (Alcon): Enhanced irrigating solution with bicarbonate, dextrose, and glutathione. Approved for all intraocular procedures. Superior endothelial protection. Higher cost but larger volume (250-500 mL).
• Navstel: Balanced salt solution with hypromellose, dextrose, and glutathione. FDA-approved for intraocular irrigation.
• Endosol Extra: Intraocular irrigating solution offering an alternative to Alcon-manufactured products.

For a patient-facing comparison that you can share with your patients, see: Alternatives to BSS Ophthalmic Solution.

Looking Ahead

The structural factors driving BSS supply vulnerability — manufacturer consolidation, regulatory barriers to entry, and rising surgical volume — are unlikely to change rapidly. Providers should plan for ongoing supply management challenges and build resilience into their procurement processes.

Key actions for 2026:

1. Diversify supplier relationships — maintain at least two to three distribution channels for BSS products
2. Stock alternative irrigating solutions as backup
3. Monitor ASHP and FDA databases for shortage alerts
4. Use Medfinder for Providers for real-time availability tracking
5. Communicate proactively with patients about potential scheduling adjustments

Final Thoughts

BSS Ophthalmic Solution remains a cornerstone of ophthalmic surgery, and supply challenges — while manageable — require active attention from providers and practice administrators. The practices that navigate this best are those that diversify their supply chains, maintain formulary flexibility, and leverage real-time tracking tools.

For the latest shortage data and availability information, visit Medfinder for Providers.